Passage Bio Announces Maxine Gowen as Chairwoman of the Board of Directors
September 07, 2021 at 12:00 pm
Share
Passage Bio, Inc. reported that Maxine Gowen, Ph.D., has been appointed chairwoman of the board of directors for the company, effective August 31. Dr. Gowen is an accomplished biopharmaceutical executive who has deep operational and research and development experience. Dr. Gowen has been a member of Passage Bio’s board since February 2021 and currently serves on the Nominating and Corporate Governance Committee. She will continue to serve on this committee in her capacity as board chairwoman.
Passage Bio, Inc. is a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases. Its clinical product candidate, PBFT02, seeks to elevate progranulin levels to restore lysosomal function and slow disease progression across a variety of neurodegenerative diseases. PBFT02 utilizes an adeno-associated virus capsid to deliver a functional granulin gene, or GRN, encoding progranulin to the brain via intra cisterna magna administration. The lead indication for PBFT02 is frontotemporal dementia, or FTD, caused by progranulin deficiency, or FTD-GRN. Its development programs consist of PBFT02 for the treatment of FTD-GRN, PBFT02 for the treatment of FTD-C9orf72 and amyotrophic lateral sclerosis, and PBFT02 for the treatment of Alzheimerâs disease. Its clinical product candidates include PBGM01, PBKR03 and PBML04. It has one unnamed preclinical research program that explores multiple potential treatment targets for Huntington's disease.